Mural Oncology Price Target Announced at $18.00/Share by HC Wainwright & Co.
Express News | Mural Oncology PLC : H.c. Wainwright Initiates Coverage With Buy Rating
Raymond James Initiates Mural Oncology(MURA.US) With Buy Rating, Announces Target Price $18
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
12 Health Care Stocks Moving In Friday's Pre-Market Session
Mural Oncology Analyst Ratings
Raymond James Initiates Mural Oncology at Strong Buy With $18 Price Target
Morgan Stanley Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $13
Mural Oncology's Investor Day Highlights Cancer Treatment Trials
Mural Oncology To Host Virtual Investor Day, Provide New Clinical Insight Into Trial Design, Statistical Assumptions, And Progress Of Late-stage Trials Of Nemvaleukin
Mural Oncology Appoints New Director and Audit Chair
Express News | Mural Oncology Strengthens Board of Directors With the Appointment of Sachiyo Minegishi
Press Release: Mural Oncology Strengthens Board of Directors With the Appointment of Sachiyo Minegishi
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
Morgan Stanley Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $13
Morgan Stanley analyst Judah Frommer maintains $Mural Oncology(MURA.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 48.4%
Buy Rating Affirmed for Mural Oncology Plc on Promising Clinical Trials and Innovative Cancer Therapies
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
Mural Oncology to Present at Two Upcoming Investor Conferences
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Mural Oncology | 10-Q: Q2 2024 Earnings Report